Core cross-linked hyaluronan-styrylpyridinium micelles as a novel carrier for paclitaxel

Tao, Youhua; Xu, Jing; Chen, Mingqing; Bai, Huiyu; Liu, Xiaoya

doi:10.1016/j.carbpol.2011.11.075

Cited by 20 publications

(13 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As Saadat et al added more drug per milligram of HA-conjugated phospholipid polymer, they observed a lower EE% for both HA-DMPE and HA-DSPE; accordingly, they proposed that this points to a possible maximum drug-loading percentage achievable in micelle formulation [47]. Furthermore, their observed inverse correlation between the drug:polymer ratio and EE% is consistent with the results of other reports on micelle formation [48,49]. …”

Section: Ha-based Micelles As a Trojan Horse For Cancer Therapysupporting

confidence: 71%

Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy

Wickens

Alsaab

Kesharwani

et al. 2017

Drug Discovery Today

167

View full text Add to dashboard Cite

The cluster-determinant 44 (CD44) receptor has a high affinity for hyaluronic acid (HA) binding and is a desirable receptor for active targeting based on its overexpression in cancer cells compared with normal body cells. The nanocarrier affinity can be increased by conjugating drug-loaded carriers with HA, allowing enhanced cancer cell uptake via the HA-CD44 receptor-mediated endocytosis pathway. In this review, we discuss recent advances in HA-based nanocarriers and micelles for cancer therapy. In vitro and in vivo experiments have repeatedly indicated HA-based nanocarriers to be a target-specific drug and gene delivery platform with great promise for future applications in clinical cancer therapy.

show abstract

Section: Ha-based Micelles As a Trojan Horse For Cancer Therapysupporting

confidence: 71%

Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy

Wickens

Alsaab

Kesharwani

et al. 2017

Drug Discovery Today

167

View full text Add to dashboard Cite

show abstract

“…But the formulation can induce severe side effects if administered by intravenous injection, such as allergic reactions, renal toxicity, neurotoxicity, hypersensitivity, and dyspnea in patients. 31 Researchers have been working hard to solve poor solubility and nonspecific biodistribution. Abraxane ® , a formulation of albumin-PTX nanoparticles approved by FDA in 2006, was reported to be able to improve the antitumor efficacy, but there was no improvement in pharmacokinetic properties compared with Taxol, because of poor colloidal stability of Abraxane.…”

Section: Introductionmentioning

confidence: 99%

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex</p>

Chu¹,

Huang

Wang³

et al. 2019

IJN

View full text Add to dashboard Cite

BackgroundIntratumoral injection is a palliative treatment that aims at further improvement in the survival and quality of life of patients with advanced or recurrent carcinomas, or cancer patients with severe comorbidities or those with a poor performance status.MethodsIn this study, a solvent-injection method was used to prepare paclitaxel–cholesterol complex-loaded lecithin–chitosan nanoparticles (PTX-CH-loaded LCS_NPs) for intratumoral injection therapy, and the physicochemical properties of NPs were well characterized.ResultsThe particle size and zeta potential of PTX-CH-loaded LCS_NPs were 142.83±0.25 nm and 13.50±0.20 mV, respectively. Release behavior of PTX from PTX-CH-loaded LCS_NPs showed a pH-sensitive pattern. The result of cell uptake assay showed that PTX-CH-loaded LCS_NPs could effectively enter cells via the energy-dependent caveolae-mediated endocytosis and macropinocytosis in company with the Golgi apparatus. Meanwhile, PTX-CH-loaded LCS_NPs had a better ability to induce cell apoptosis than PTX solution. The in vivo antitumor results suggested that PTX-CH-loaded LCS_NPs effectively inhibited mouse mammary cancer growth and metastasis to distant organs and significantly improved the survival rate of tumor-bearing mice by intratumoral administration.ConclusionIn general, our study demonstrated that PTX-CH-loaded LCS_NPs used for palliative treatment by intratumoral injection showed improved safety and antitumor efficacy, which provided an alternative approach in the field of palliative chemotherapy.

show abstract

“…Hence, many attempts have been devoted to substitute the Cremophor Õ EL-based formulation with alternative carriers which enable delivering PTX selectively to the tumor tissues with significantly reduced adverse effects on normal cells. Numerous drug delivery systems including parenteral emulsions (He et al, 2003;Nornoo et al, 2008), liposomes (Fetterly et al, 2003;Soenpenberg et al, 2004), nanoparticles (Hawkins et al, 2008;Zhu et al, 2010) and polymeric micelles (Qu et al, 2009;Tao et al, 2012;Qu et al, 2013;Wang et al, 2013) have extensively been studied and evaluated for parenteral delivery of PTX into cancer cells.…”

Section: Introductionmentioning

confidence: 99%

In vivopharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle

Rezazadeh¹,

Emami²,

Hasanzadeh³

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

A water-insoluble anti-tumor agent, paclitaxel (PTX) was successfully incorporated into noveltargeted polymeric micelles based on tocopherol succinate-chitosan-polyethylene glycol-folic acid (PTX/TS-CS-PEG-FA). The aim of the present study was to evaluate the pharmacokinetics, tissue distribution and efficacy of PTX/TS-CS-PEG-FA in comparison to Anzatax Õ in tumor bearing mice. The micellar formulation showed higher in vitro cytotoxicity against mice breast cancer cell line, 4T1, due to the folate receptor-mediated endocytosis. The IC 50 value of PTX, a concentration at which 50% cells are killed, was 1.17 and 0.93 mM for Anzatax Õ and PTX/TS-CS-PEG-FA micelles, respectively. The in vivo anti-tumor efficacy of PTX/TS-CS-PEG-FA, as measured by reduction in tumor volume of 4T1 mouse breast cancer injected in Balb/c mice was significantly greater than that of Anzatax Õ . Pharmacokinetic study in tumor bearing mice revealed that the micellar formulation prolonged the systemic circulation time of PTX and the AUC of PTX/TS-CS-PEG-FA was obtained 0.83-fold lower than Anzatax Õ . Compared with Anzatax Õ , the V d , T 1/2ß and MRT of PTX/TS-CS-PEG-FA was increased by 2.76, 2.05 and 1.68-fold, respectively. As demonstrated by tissue distribution, the PTX/TS-CS-PEG-FA micelles increased accumulation of PTX in tumor, therefore, resulted in anti-tumor effects enhancement and drug concentration in the normal tissues reduction. Taken together, our evaluations show that PTX/TS-CS-PEG-FA micelle is a potential drug delivery system of PTX for the effective treatment of the tumor and systematic toxicity reduction, thus, the micellar formulation can provide a useful alternative dosage form for intravenous administration of PTX. KeywordsBiodistribution, in vivo anti-tumor effect, Paclitaxel, pharmacokinetics, targeted polymeric micelle History

show abstract

Core cross-linked hyaluronan-styrylpyridinium micelles as a novel carrier for paclitaxel

Cited by 20 publications

References 41 publications

Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy

Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex</p>

In vivopharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle

Contact Info

Product

Resources

About

Core cross-linked hyaluronan-styrylpyridinium micelles as a novel carrier for paclitaxel

Cited by 20 publications

References 41 publications

Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy

Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin&ndash;chitosan nanoparticles loading paclitaxel&ndash;cholesterol complex</p>

In vivopharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle

Contact Info

Product

Resources

About

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex</p>